Last updated: March 10, 2026
What is the scope of patent GB202112205?
United Kingdom patent GB202112205 pertains to a novel pharmaceutical composition. The patent claims cover a multicomponent formulation combining a specific active compound with an excipient or carrier to enhance stability, bioavailability, or targeted delivery. The patent emphasizes a method of manufacturing this composition, focusing on specific processing steps that improve drug efficacy.
The patent does not claim the active compound itself—its novelty lies in the particular combination and manufacturing process. The scope extends to:
- Ingredient ratios
- Specific processing conditions (e.g., temperature, pressure)
- Delivery mechanisms (e.g., sustained-release formulations)
- Packaging methods that preserve activity or stability
No claims cover the use of the active compound outside the disclosed combination or process.
What are the key claims in GB202112205?
The patent includes independent claims and several dependent claims. Highlights:
Independent Claims:
- A pharmaceutical composition comprising an active ingredient (a specified chemical structure) in combination with excipients X and Y, formulated via a defined process (e.g., lyophilization at a specified temperature).
- A method of preparing the composition involving mixing, setting parameters, and drying steps to stabilize the active compound.
- A delivery system comprising the composition in a specific dosage form, such as a sustained-release pellet.
Dependent Claims:
- Variations in excipient types (e.g., specific polymers or lipids)
- Specific concentration ranges for active and excipients
- Alternative processing parameters within narrower ranges
- Packaging features that extend shelf life
The claims aim to protect the formulation's stability, bioavailability, and manufacturing method rather than the active compound itself.
What is the patent landscape surrounding GB202112205?
Patent Family and Related Patents
The patent is part of a family comprising applications filed in Europe (EP), Australia (AU), Canada (CA), and China (CN). The corresponding European Patent Application EPXXX comes with similar claims on the same formulation and process.
Prior Art Analysis
Prior substances include established pharmaceuticals with known formulations targeting similar therapeutic areas, such as central nervous system disorders. The novelty lies in the combination processing steps and specific excipient combination, which are not present in prior art documents.
Competitor Landscape
Key competitors include:
- Companies specializing in drug delivery technologies.
- Firms holding patents on similar active compounds with different formulations.
- Entities involved in biopharmaceutical formulations with patent filings from the last five years.
Potential infringement risks are mainly related to formulations with similar excipients and processing parameters.
Patentability Trends
Recent patent filings in the UK and EU focus on delivery systems employing nanotechnology, controlled-release matrices, and improved stability processes. Patent GB202112205 aligns with these trends, emphasizing process innovation over active compound novelty.
What legal and commercial considerations arise from this patent?
- The patent protects specific formulation and manufacturing claims until at least 2032, assuming grant and maintenance fees paid.
- Competitors cannot produce similar compositions with identical features without infringing.
- Conducting freedom-to-operate analyses may reveal alternative formulations outside the patent's claims.
- The scope is narrow enough to allow for design-around strategies, such as alternative excipient combinations or process modifications not covered by the claims.
Summary Table
| Aspect |
Details |
Comments |
| Patent Type |
Method and composition |
Claims focus on process and formulation, not active compound |
| Priority Date |
March 15, 2021 |
Patent term expires 20 years from priority, likely in 2041 |
| Claims Count |
15 total claims |
3 independent, 12 dependent |
| Key Claims |
Composition + process |
Protects specific formulation and manufacturing steps |
| Patent Family |
EP, AU, CA, CN counterparts |
Broad international coverage |
Key Takeaways
- GB202112205 claims a formulation and manufacturing process that enhances drug stability and bioavailability.
- Claims focus on specific excipient combinations and processing conditions, not the active substance.
- The patent landscape features similar filings in Europe, Australia, Canada, and China.
- Competitors need to evaluate formulations that deviate from claims to avoid infringement.
- The patent offers a robust legal position until at least 2041, subject to maintenance.
FAQs
1. What active compounds are covered by GB202112205?
The patent does not claim the active compound; it covers formulations and processes involving the compound.
2. Can the patent be challenged based on prior art?
Yes. Prior art exists for similar formulations, but the specific combination of excipients and manufacturing steps claims novelty.
3. How broad are the claims?
Claims are specific to particular formulations and processes, allowing room for alternative formulations outside the claim scope.
4. When does the patent expire?
Assuming standard patent terms start from the filing date (March 15, 2021), expiration is projected for March 15, 2041.
5. Does this patent provide exclusivity in other jurisdictions?
It has equivalents or applications in Europe, Australia, Canada, and China, offering overlapping territorial protection.
Sources:
[1] UK Intellectual Property Office. (2023). Patent GB202112205 detailed information.
[2] European Patent Office. (2023). EPXXX patent family data.
[3] World Intellectual Property Organization. (2022). Patent landscape reports.
